London Cartilage Clinic
Explore expert articles on cartilage care, regenerative treatments, and practical recovery advice from our specialist team.
The single most consistent finding in knee osteoarthritis is not cartilage loss but quadriceps weakness. When thigh muscles fail to absorb compressive forces, cartilage receives shock it was not designed to bear—a pattern that structured strengthening reverses.
ChondroFiller is an injectable collagen scaffold that recruits the body's own repair cells to fill focal knee cartilage defects; the single-stage outpatient procedure produces IKDC improvements of approximately 30 points with reoperation rates of 3–8%.
Candidacy for ChondroFiller injection rests on three interlocking criteria — cartilage-defect size, osteoarthritis grade, and joint-alignment stability — assessed together; meeting all three determines whether the injectable or surgical pathway applies.
Nocturnal hip pain signals a shift from activity-triggered to persistent inflammation — advancing disease where specialist assessment becomes necessary to preserve access to joint-preserving treatments before options close.
Severe knee osteoarthritis damages both the cartilage surface and the synovial membrane. For Kellgren–Lawrence grade III or IV patients considering replacement surgery, the dual injection protocol addresses both in one visit: ChondroFiller scaffolds cartilage repair whilst Arthrosamid buffers the synovial lining.
ChondroFiller injection rebuilds shoulder cartilage defects by delivering a self-gelling Type I collagen scaffold that recruits the patient's own cells to regenerate tissue over 12 months, without general anaesthetic or surgery.
